Stay updated with breaking news from Operations Items. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1Presented preclinical data from LNCB74 at recent AACR annual meeting Cash of approximately $96.0 million...
12.03.2024 - IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in dose escalation and initial mesothelioma patient ...
14.03.2023 - Focused targeted oncology pipeline advancing towards multiple near-term milestones; runway into 2025 Novel paralog-selective TEAD inhibitor, IK-930, advanced through multiple dose escalation cohorts, Fast Track and Orphan designations granted; ...
Discontinuing development of our NC318 programAdvancing clinical pipeline: NC410 combination, NC525, and NC762 Extending runway into mid-2025 (an...
Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results License option agreement with Novartis for target-specific access... | March 8, 2022